BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

Huahui Health And BeOne Medicines Forge Global Deal For Trispecific Antibody HH160

Huahui Health announced that it has entered into a global exclusive option, license and collaboration agreement with BeOne Medicines for HH160, a...

May 02, 2026 | News

Sonire Therapeutics Initiates SUNRISE II Trial To Advance Non Invasive HIFU Therapy For Pancreatic Cancer In The United States

SUNRISE-II feasibility trial marks the company's entry into U.S. clinical development, advancingminimally invasive, anesthesia-free treatment approach PAL...

May 02, 2026 | News

Henlius And Organon Secure European Approval For First Pertuzumab Biosimilar POHERDY

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHE...

May 01, 2026 | News

Kyowa Kirin Co., Ltd. And Kura Oncology, Inc. Advance Ziftomenib With Japan Phase 2 Trial In NPM1 Mutated AML

Regulatory Filing in Japan Planned Following Clinical Trial Completion – Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura...

April 27, 2026 | News

Leinco Technologies And CellCarta Partner To Advance Proteomics In Immuno Oncology

Leinco Technologies, a leader in antibody and protein development, and CellCarta, a global provider of precision medicine laboratory services, are ple...

April 22, 2026 | News

Akamis Bio Reports Promising Early Efficacy For NG 350A In Rectal Cancer Study

NG-350A combined with chemoradiotherapy demonstrated promising efficacy and a favorable safety profile Composite response rate of 50 percent observed ac...

April 21, 2026 | News

Samsung Bioepis Initiates Phase 1 Clinical Trial for Novel ADC Candidate SBE303 Targeting Nectin 4

Samsung Bioepis Co., Ltd. announced the initiation of a Phase 1 clinical trial for SBE303, its first novel antibody drug conjugate candidate designed...

April 16, 2026 | News

Kazia Therapeutics Expands Oncology Pipeline With SETDB1 Targeted Epigenetic Platform

Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment re...

April 15, 2026 | News

Oricell Therapeutics Raises Over USD 110 Million To Accelerate Global CAR T Innovation

Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, announc...

April 13, 2026 | News

Lumonus And Memorial Sloan Kettering Cancer Center Collaborate To Scale Automated Radiation Therapy Planning

Lumonus, the company behind Lumonus AI, a platform for radiation oncology clinical workflow and automated treatment planning, announced a collaboration wit...

April 09, 2026 | News

IDEAYA Biosciences Advances IDE574 Into Phase 1 As First Patient Enrolled For KAT6 And KAT7 Dual Inhibitor

Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency...

April 07, 2026 | News

Syneron Bio Secures Series B Financing To Advance Macrocyclic Peptide Discovery Platform And Clinical Pipeline

Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on Marc...

April 06, 2026 | News

CellCarta And Pillar Biosciences Partner To Accelerate NGS Tumor Profiling For Biomarker Driven Oncology Trials

CellCarta, a global provider of precision medicine laboratory services for drug development, and Pillar Biosciences, a leader in NGS-based oncology molecul...

April 03, 2026 | News

Abbisko Therapeutics Secures EMA Orphan Drug Status For Irpagratinib In Liver Cancer

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, highly selective, oral...

April 02, 2026 | News

Stay Connected